{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:11:34Z","timestamp":1770833494469,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,1,23]],"date-time":"2008-01-23T00:00:00Z","timestamp":1201046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s00280-007-0673-7","type":"journal-article","created":{"date-parts":[[2008,1,22]],"date-time":"2008-01-22T14:25:56Z","timestamp":1201011956000},"page":"849-855","source":"Crossref","is-referenced-by-count":121,"title":["S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study"],"prefix":"10.1007","volume":"62","author":[{"given":"Junji","family":"Furuse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narikazu","family":"Boku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Ohkawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Masumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"issue":"9","key":"673_CR1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdh351","volume":"15","author":"T Andre","year":"2004","unstructured":"Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 15(9):1339\u20131343","journal-title":"Ann Oncol"},{"issue":"8","key":"673_CR2","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/sj.bjc.6601736","volume":"90","author":"DC Doval","year":"2004","unstructured":"Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S et al (2004) A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 90(8):1516\u20131520","journal-title":"Br J Cancer"},{"issue":"6","key":"673_CR3","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","volume":"54","author":"G Falkson","year":"1984","unstructured":"Falkson G, MacIntyre JM, Moertel CG (1984) Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54(6):965\u2013969","journal-title":"Cancer"},{"key":"673_CR4","first-page":"16s","volume":"23","author":"J Furuse","year":"2005","unstructured":"Furuse J, Okusaka T, Funakoshi A, Boku N, Yamao K, Ohkawa S et al (2005) A phase II study of S-1 in patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol 23:16s (Abstract No: 4104)","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"9","key":"673_CR5","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jjco\/hyl075","volume":"36","author":"J Furuse","year":"2006","unstructured":"Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H et al (2006) Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol 36(9):552\u2013556","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"673_CR6","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1023\/A:1012543223020","volume":"12","author":"JO Gallardo","year":"2001","unstructured":"Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C et al (2001) A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 12(10):1403\u20131406","journal-title":"Ann Oncol"},{"issue":"6","key":"673_CR7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7(6):593\u2013600","journal-title":"Ann Oncol"},{"key":"673_CR8","unstructured":"Haskell CM (ed) (2001) Cancer treatment, 5th edn. WB Saunders Co, Philadelphia"},{"issue":"7","key":"673_CR9","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0959-8049(97)10166-6","volume":"34","author":"M Hejna","year":"1998","unstructured":"Hejna M, Pruckmayer M, Raderer M (1998) The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer 34(7):977\u2013986","journal-title":"Eur J Cancer"},{"issue":"8","key":"673_CR10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/jjco\/hyi131","volume":"35","author":"M Ikeda","year":"2005","unstructured":"Ikeda M, Okusaka T, Ueno H, Morizane C, Furuse J, Ishii H (2005) A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. Jpn J Clin Oncol 35(8):439\u2013443","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"673_CR11","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1054\/bjoc.2001.2031","volume":"85","author":"M Kawahara","year":"2001","unstructured":"Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S et al (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85(7):939\u2013943","journal-title":"Br J Cancer"},{"issue":"7","key":"673_CR12","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/annonc\/mdg281","volume":"14","author":"TW Kim","year":"2003","unstructured":"Kim TW, Chang HM, Kang HJ, Lee JR, Ryu MH, Ahn JH et al (2003) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer. Ann Oncol 14(7):1115\u20131120","journal-title":"Ann Oncol"},{"issue":"10","key":"673_CR13","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","volume":"23","author":"JJ Knox","year":"2005","unstructured":"Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23(10):2332\u20132338","journal-title":"J Clin Oncol"},{"issue":"5","key":"673_CR14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/annonc\/mdh172","volume":"15","author":"JJ Knox","year":"2004","unstructured":"Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ (2004) Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol 15(5):770\u2013774","journal-title":"Ann Oncol"},{"key":"673_CR15","unstructured":"Koyama Y (ed) (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28:101\u2013130"},{"issue":"Suppl 4","key":"673_CR16","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/10.suppl_4.S129","volume":"10","author":"B Levin","year":"1999","unstructured":"Levin B (1999) Gallbladder carcinoma. Ann Oncol 10(Suppl 4):129\u2013130","journal-title":"Ann Oncol"},{"issue":"3","key":"673_CR17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000070622","volume":"49","author":"MH Lin","year":"2003","unstructured":"Lin MH, Chen JS, Chen HH, Su WC (2003) A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 49(3):154\u2013158","journal-title":"Chemotherapy"},{"key":"673_CR18","unstructured":"Makuuchi M (ed) (2000) The general rules for the clinical and pathological study of primary liver cancer November 2000, 4th edn. Kanehara, Tokyo"},{"issue":"1","key":"673_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/A:1006268018519","volume":"17","author":"S Mani","year":"1999","unstructured":"Mani S, Sciortino D, Samuels B, Arrietta R, Schilsky RL, Vokes EE et al (1999) Phase II trial of uracil\/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs 17(1):97\u2013101","journal-title":"Invest New Drugs"},{"key":"673_CR20","unstructured":"Nagakawa T (ed) (2003) General rules for surgical and pathological studies on cancer of the biliary tract September 2003, 5th edn. Kanehara, Tokyo"},{"key":"673_CR21","unstructured":"Nomura K (ed) (2005) Cancer statistics in Japan 2005. Foundation for Promotion of Cancer Research (FPCR), Tokyo"},{"issue":"2","key":"673_CR22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1054\/bjoc.2000.1236","volume":"83","author":"A Ohtsu","year":"2000","unstructured":"Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K et al (2000) Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 83(2):141\u2013145","journal-title":"Br J Cancer"},{"issue":"5","key":"673_CR23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-005-0095-3","volume":"57","author":"T Okusaka","year":"2006","unstructured":"Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S et al (2006) Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 57(5):647\u2013653","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"673_CR24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/cncr.20368","volume":"101","author":"YZ Patt","year":"2004","unstructured":"Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA et al (2004) Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 101(3):578\u2013586","journal-title":"Cancer"},{"issue":"8","key":"673_CR25","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.1996.14.8.2311","volume":"14","author":"YZ Patt","year":"1996","unstructured":"Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I et al (1996) Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14(8):2311\u20132315","journal-title":"J Clin Oncol"},{"issue":"2","key":"673_CR26","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/BF02968301","volume":"11","author":"T Saeki","year":"2004","unstructured":"Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S et al (2004) A phase II study of S-1 in patients with metastatic breast cancer\u2014a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 11(2):194\u2013202","journal-title":"Breast Cancer"},{"issue":"11","key":"673_CR27","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0959-8049(98)00211-1","volume":"34","author":"Y Sakata","year":"1998","unstructured":"Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34(11):1715\u20131720","journal-title":"Eur J Cancer"},{"issue":"5","key":"673_CR28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548\u2013557","journal-title":"Anticancer Drugs"},{"issue":"3","key":"673_CR29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"673_CR30","doi-asserted-by":"crossref","unstructured":"Ueno H, Furuse J, Yamao K, Funakoshi A, Boku N, Ohkawa S et al (2007) A multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. ASCO 2007 Gastrointestinal Cancers Symposium (Abstract No: 148)","DOI":"10.1200\/jco.2007.25.18_suppl.4550"},{"issue":"10","key":"673_CR31","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/sj.bjc.6602208","volume":"91","author":"H Ueno","year":"2004","unstructured":"Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91(10):1769\u20131774","journal-title":"Br J Cancer"},{"issue":"Pt 1","key":"673_CR32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1258\/000456303321016150","volume":"40","author":"AB Kuilenburg van","year":"2003","unstructured":"van Kuilenburg AB, De Abreu RA, van Gennip AH (2003) Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency. Ann Clin Biochem 40(Pt 1):41\u201345","journal-title":"Ann Clin Biochem"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0673-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-007-0673-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-007-0673-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T02:47:34Z","timestamp":1588301254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-007-0673-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1007\/s00280-007-0673-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,23]]}}}